Oral administration of Bifidobacterium longum prevents gut-derived Pseudomonas aeruginosa sepsis in mice

Journal of Applied Microbiology

Volumn 104, Issue 3, 2008, Pages 672-680

  Matsumoto, T ^a   Ishikawa, H ^a   Tateda, K ^b   Yaeshima, T ^c   Ishibashi, N ^c   Yamaguchi, K ^b  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MORINAGA MILK INDUSTRY CO LTD   (Japan)

Author keywords

Bifidobacterium longum; Probiotics; Pseudomonas aeruginosa; Sepsis

Indexed keywords

BACTERIA; BLOOD; CELLS; CYTOLOGY; MAMMALS; MONOLAYERS;

BIFIDOBACTERIUM LONGUM; LEUCOPENIA; ORAL ADMINISTRATION; ORAL INOCULATION; P.AERUGINOSA; PROBIOTICS; PSEUDOMONAS AERUGINOSA; SEPSIS; SURVIVAL RATE; VIABLE COUNT;

PROBIOTICS;

CYCLOPHOSPHAMIDE; EXCIPIENT; PROBIOTIC AGENT;

BACTERIAL DISEASE; DISEASE CONTROL; EXPERIMENTAL STUDY; IMMUNOCOMPETENCE; PROBIOTICS; RODENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM CULTURE; BIFIDOBACTERIUM LONGUM; BLOOD; CELL ADHESION; CELL STRAIN CACO 2; COLONY FORMING UNIT; CONTROLLED STUDY; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; JEJUNUM; LEUKOPENIA; LIVER; MONOLAYER CULTURE; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; PSEUDOMONAS AERUGINOSA; SEPSIS;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; MUS; PSEUDOMONAS AERUGINOSA;

EID: 39149088919     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/j.1365-2672.2007.03593.x     Document Type: Article

References (31)

1. Aiba, Y., Ishikawa, H., Shimizu, K., Noda, S., Kitada, Y., Sasaki, M. Koga, Y. (2002) Role of internalization in the pathogenicity of Shiga toxin-producing Escherichia coli infection in a gnotobiotic murine model. Microbiol Immunol 46, 723 731.
2. Akyol, S., Mas, M.R., Comert, B., Ateskan, U., Yasar, M., Aydogan, H., Deveci, S., Akay, C. et al. (2003) The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis. Pancreas 26, 363 367.
3. Anderson, A.D., Mcnaught, C.E., Jain, P.K. Macfie, J. (2004) Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 53, 241 245.
4. Araya-Kojima, T., Yaeshima, T., Ishibashi, N., Shimamura, S. Hayasawa, H. (1995) Inhibitory effects of Bifidobacterium longum BB536 on harmful intestinal bacteria. Bifidobacteria Microflora 14, 59 66.
5. Bauer, T.M., Fernandez, J., Navasa, M., Vila, J. Rhodes, J. (2002) Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol 36, 501 506.
6. Chen, C.C., Louie, S., Shi, H.N. Walker, W.A. (2005) Preinoculation with the probiotic Lactobacillus acidophilus early in life effectively inhibits murine Citrobacter rodentium colitis. Pediatr Res 58, 1185 1191.
7. De Waard, R., Garssen, J., Bokken, G.C. Vos, J.G. (2002) Antagonistic activity of Lactobacillus casei strain shirota against gastrointestinal Listeria monocytogenes infection in rats. Int J Food Microbiol 73, 93 100.
8. Gibson, G.R. Wang, X. (1994) Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 77, 412 420.
9. Hirakata, Y., Kaku, M., Mizukane, R., Ishida, K., Furuya, N., Matsumoto, T., Tateda, K. Yamaguchi, K. (1992) Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa. Antimicrob Agents Chemother 36, 1922 1927.
10. Johnson-Henry, K.C., Nadjafi, M., Avitzur, Y., Mitchell, D.J., Ngan, B.Y., Galindo-Mata, E., Jones, N.L. Sherman, P.M. (2005) Amelioration of the effects of Citrobacter rodentium infection in mice by pretreatment with probiotics. J Infect Dis 191, 2106 2117.
11. Lievin, V., Peiffer, I., Hudault, S., Rochat, F., Brassart, D., Neeser, J.R. Servin, A.L. (2000) Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 47, 646 652.
12. Matsumoto, T., Tateda, K., Miyazaki, S., Furuya, N., Ohno, A., Ishii, Y., Hirakata, Y. Yamaguchi, K. (1997) Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 41, 308 313.
13. Matsumoto, T., Tateda, K., Furuya, N., Miyazaki, S., Ohno, A., Ishii, Y., Hirakata, Y. Yamaguchi, K. (1998a) Efficacies of alkaline protease, elastase, and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice. J Med Microbiol 47, 303 308.
14. Matsumoto, T., Tateda, K., Miyazaki, S., Furuya, N., Ohno, A., Ishii, Y., Hirakata, Y. Yamaguchi, K. (1998b) Effect of immunisation with Pseudomonas aeruginosa on gut-derived sepsis in mice. J Med Microbiol 47, 295 301.
15. Matsumoto, T., Tateda, K., Miyazaki, S., Furuya, N., Ohno, A., Ishii, Y., Hirakata, Y. Yamaguchi, K. (1998c) Effect of interleukin-10 on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 42, 2853 2857.
16. Medici, M., Vinderola, C.G., Weill, R. Perdigon, G. (2005) Effect of fermented milk containing probiotic bacteria in the prevention of an enteroinvasive Escherichia coli infection in mice. J Dairy Res 72, 243 249.
17. Naaber, P., Mikelsaar, R.H., Salminen, S. Mikelsaar, M. (1998) Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol 47, 591 598.
18. Namba, K., Yaeshima, T., Ishibashi, N., Hayasawa, H. Yamazaki, S. (2003) Inhibitory effects of Bifidobacterium longum on enterohemorrhagic Escherichia coli O157:H7. Biosci Microflora 22, 85 91.
19. O'Riordan, K. Fitzgerald, G.F. (1998) Evaluation of bifidobacteria for the production of antimicrobial compounds and assessment of performance in cottage cheese at refrigeration temperature. J Appl Microbiol 85, 103 114.
20. Ouwehand, A., Salvadori, B.B., Fonden, R., Mogensen, G., Salminen, S. Sellars, R. (2003) Health effects of probiotics and culture-containing dairy products in humans. Bull IDF 380, 4 19.
21. Ramphal, R. (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39 (Suppl. 1 S25 S31.
22. Rayes, N., Hansen, S., Seehofer, D., Muller, A.R., Serke, S., Bengmark, S. Neuhaus, P. (2002) Early enteral supply of fiber and lactobacilli versus conventional nutrition: a controlled trial in patients with major abdominal surgery. Nutrition 18, 609 615.
23. Seehofer, D., Rayes, N., Schiller, R., Stockmann, M., Muller, A.R., Schirmeier, A., Schaeper, F., Tullius, S.G. et al. (2004) Probiotics partly reverse increased bacterial translocation after simultaneous liver resection and colonic anastomosis in rats. J Surg Res 117, 262 271.
24. Shu, Q. Gill, H.S. (2002) Immune protection mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20) against Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol 34, 59 64.
25. Steidler, L. (2003) Genetically engineered probiotics. Best Pract Res Clin Gastroenterol 17, 861 876.
26. Takahashi, M., Taguchi, H., Yamaguchi, H., Osaki, T., Komatsu, A. Kamiya, S. (2004) The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol 41, 219 226.
27. Torre, D., Ferrario, G., Speranza, F., Martegani, R. Zeroli, C. (1996) Increased levels of nitrite in the sera of children infected with human immunodeficiency virus type 1. Clin Infect Dis 22, 650 653.
28. Yamazaki, S., Tsuyuki, S., Akashiba, H., Kamimura, H., Kimura, M., Kawashima, T. Ueda, K. (1991) Immune response of Bifidobacterium-monoassociated mice. Bifidobacteria Microflora 10, 19 31.
29. Yildirim, Z. Johnson, M. (1998) Characterization and antimicrobial spectrum of bifidocin B, a bacteriocin produced by Bifidobacterium bifidum NCFB 1454. J Food Prot 61, 47 51.
30. Yildirim, Z., Winters, D.K. Johnson, M.G. (1999) Purification, amino acid sequence and mode of action of bifidocin B produced by Bifidobacterium bifidum NCFB 1454. J Appl Microbiol 86, 45 54.
31. Yin, X.H., Mikamo, H. Tamaya, T. (2003) Nosocomial infectious potency of imipenem-resistant Pseudomonas aeruginosa isolated from obstetric and gynecologic infections. J Infect Chemother 9, 97 100.